Clovis Oncology (CLVS) – Business Wire
-
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
-
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat
-
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress
-
TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations
-
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
-
Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer
-
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups
-
Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
-
Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
-
NorthStar Medical Radioisotopes Announces Supply Agreement with Clovis Oncology for Therapeutic Radioisotope Actinium-225 (Ac-225)
-
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting
-
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regard
-
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
-
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
-
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
-
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
-
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022
-
Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phas
-
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
-
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an
-
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones
-
Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call
-
Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021
-
Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit
-
Clovis Oncology Announces Third Quarter 2021 Operating Results
-
Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3
-
ITM and Clovis Oncology Announce Lutetium-177 Clinical Supply Agreement
-
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
-
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
-
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program
-
Clovis Oncology Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland
-
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program
-
Clovis Oncology Announces Second Quarter 2021 Operating Results
-
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
-
Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
-
Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
-
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
-
Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders
-
Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting
-
Clovis Oncology Announces At-The-Market Equity Offering Program
-
Clovis Oncology Announces First Quarter 2021 Operating Results
-
Clovis Oncology to Present at the Bank of America 2021 Health Care Conference
-
Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5
-
Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021
-
Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation
-
Clovis Oncology Announces 2020 Operating Results
-
Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February 23
-
Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
-
Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
-
Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020
Back to CLVS Stock Lookup
